LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Russell, Roslin"
  2. AU=Kim Ka Young
  3. AU="Mateja, Allyson"
  4. AU="Todorov, Alexander B."
  5. AU=Mosallanezhad Behzad
  6. AU=Rochman Yrina AU=Rochman Yrina
  7. AU="Wang, Hong-Bo"
  8. AU="Zhong, Boyu"
  9. AU=Gimeno-Costa Ricardo AU=Gimeno-Costa Ricardo
  10. AU="Wu, Jiangbo"
  11. AU="MacIntyre, Michael F"
  12. AU="Moon, H K"
  13. AU="Clark, Mindie"
  14. AU="Nichols, Aaron L"
  15. AU="Cash-Goldwasser, Shama"
  16. AU="Christopher B. Daniels"
  17. AU="Wakama, Hitoshi"
  18. AU="Crowe, K"
  19. AU="Merz, Sabine"
  20. AU=Rossolatos George
  21. AU="Nalla, Shahed"
  22. AU="Alvarado, Miriam"
  23. AU="Garduño-Sánchez, Marco"
  24. AU="Khan, Sherbano"
  25. AU="Kakava, Felicia"

Suchergebnis

Treffer 1 - 10 von insgesamt 46

Suchoptionen

  1. Buch: Microarray technology in practice

    Russell, Steven / Meadows, Lisa A. / Russell, Roslin R.

    2009  

    Verfasserangabe Steve Russell ; Lisa A. Meadows and Roslin R. Russell
    Schlagwörter DNA microarrays
    Thema/Rubrik (Code) 572.8636
    Sprache Englisch
    Umfang X, 449 S. [2] Bl. : Ill., graph. Darst., 23cm
    Ausgabenhinweis 1. ed.
    Verlag Elsevier AP
    Erscheinungsort Amsterdam u.a.
    Erscheinungsland Niederlande
    Dokumenttyp Buch
    HBZ-ID HT015767718
    ISBN 0-12-372516-X ; 978-0-12-372516-5
    Datenquelle Katalog ZB MED Medizin, Gesundheit

    Zusatzmaterialien

    Kategorien

  2. Artikel: Meeting review: Bioinformatics and Medicine - from molecules to humans, virtual and real.

    Russell, Roslin

    Comparative and functional genomics

    2008  Band 3, Heft 3, Seite(n) 270–276

    Abstract: The Industrialization Workshop Series aims to promote and discuss integration, automation, simulation, quality, availability and standards in the high-throughput life sciences. The main issues addressed being the transformation of bioinformatics and ... ...

    Abstract The Industrialization Workshop Series aims to promote and discuss integration, automation, simulation, quality, availability and standards in the high-throughput life sciences. The main issues addressed being the transformation of bioinformatics and bioinformaticsbased drug design into a robust discipline in industry, the government, research institutes and academia. The latest workshop emphasized the influence of the post-genomic era on medicine and healthcare with reference to advanced biological systems modeling and simulation, protein structure research, protein-protein interactions, metabolism and physiology. Speakers included Michael Ashburner, Kenneth Buetow, Francois Cambien, Cyrus Chothia, Jean Garnier, Francois Iris, Matthias Mann, Maya Natarajan, Peter Murray-Rust, Richard Mushlin, Barry Robson, David Rubin, Kosta Steliou, John Todd, Janet Thornton, Pim van der Eijk, Michael Vieth and Richard Ward.
    Sprache Englisch
    Erscheinungsdatum 2008-07-16
    Erscheinungsland Egypt
    Dokumenttyp Journal Article
    ZDB-ID 2043139-9
    ISSN 1532-6268 ; 1531-6912
    ISSN (online) 1532-6268
    ISSN 1531-6912
    DOI 10.1002/cfg.178
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel: Designing microarray oligonucleotide probes.

    Russell, Roslin

    Briefings in bioinformatics

    2003  Band 4, Heft 4, Seite(n) 361–367

    Mesh-Begriff(e) DNA Probes/genetics ; Oligonucleotide Array Sequence Analysis/methods ; Software
    Chemische Substanzen DNA Probes
    Sprache Englisch
    Erscheinungsdatum 2003-07-11
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 2068142-2
    ISSN 1467-5463
    ISSN 1467-5463
    DOI 10.1093/bib/4.4.361
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  4. Artikel ; Online: A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance.

    Yap, Timothy A / LoRusso, Patricia M / Wong, Deborah J / Hu-Lieskovan, Siwen / Papadopoulos, Kyriakos P / Holz, Josefin-Beate / Grabowska, Urszula / Gradinaru, Cristian / Leung, Kin-Mei / Marshall, Sylwia / Reader, Claire S / Russell, Roslin / Sainson, Richard C A / Seal, Claire J / Shepherd, Christopher J / Germaschewski, Fiona / Gliddon, Daniel / Stern, Omer / Young, Lesley /
    Brewis, Neil / Kayitalire, Louis / Morrow, Michelle

    Clinical cancer research : an official journal of the American Association for Cancer Research

    2022  Band 29, Heft 5, Seite(n) 888–898

    Abstract: Purpose: This phase 1 study (NCT03440437) evaluated the safety, tolerability, pharmacokinetics (PK), and activity of FS118, a bispecific antibody-targeting LAG-3 and PD-L1, in patients with advanced cancer resistant to anti-PD-(L)1 therapy.: Patients ... ...

    Abstract Purpose: This phase 1 study (NCT03440437) evaluated the safety, tolerability, pharmacokinetics (PK), and activity of FS118, a bispecific antibody-targeting LAG-3 and PD-L1, in patients with advanced cancer resistant to anti-PD-(L)1 therapy.
    Patients and methods: Patients with solid tumors, refractory to anti-PD-(L)1-based therapy, received intravenous FS118 weekly with an accelerated dose titration design (800 μg to 0.3 mg/kg) followed by 3+3 ascending dose expansion (1 to 20 mg/kg). Primary objectives were safety, tolerability, and PK. Additional endpoints included antitumor activity, immunogenicity, and pharmacodynamics.
    Results: Forty-three patients with a median of three prior regimens in the locally advanced/metastatic setting, including at least one anti-PD-(L)1 regimen, received FS118 monotherapy. FS118 was well tolerated, with no serious adverse events relating to FS118 reported. No dose-limiting toxicities (DLT) were observed, and an MTD was not reached. The recommended phase 2 dose of FS118 was established as 10 mg/kg weekly. The terminal half-life was 3.9 days. Immunogenicity was transient. Pharmacodynamic activity was prolonged throughout dosing as demonstrated by sustained elevation of soluble LAG-3 and increased peripheral effector cells. The overall disease control rate (DCR) was 46.5%; this disease control was observed as stable disease, except for one late partial response. Disease control of 54.8% was observed in patients receiving 1 mg/kg or greater who had acquired resistance to PD-(L)1-targeted therapy.
    Conclusions: FS118 was well tolerated with no DLTs observed up to and including 20 mg/kg QW. Further studies are warranted to determine clinical benefit in patients who have become refractory to anti-PD-(L)1 therapy. See related commentary by Karapetyan and Luke, p. 835.
    Mesh-Begriff(e) Humans ; Interferons ; B7-H1 Antigen ; Neoplasms/pathology ; Antineoplastic Agents/adverse effects ; Antibodies, Bispecific/adverse effects ; Immunotherapy ; Biology
    Chemische Substanzen Interferons (9008-11-1) ; B7-H1 Antigen ; Antineoplastic Agents ; Antibodies, Bispecific
    Sprache Englisch
    Erscheinungsdatum 2022-11-05
    Erscheinungsland United States
    Dokumenttyp Research Support, Non-U.S. Gov't ; Journal Article
    ZDB-ID 1225457-5
    ISSN 1557-3265 ; 1078-0432
    ISSN (online) 1557-3265
    ISSN 1078-0432
    DOI 10.1158/1078-0432.CCR-22-1449
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel ; Online: Double-stranded microRNA mimics can induce length- and passenger strand-dependent effects in a cell type-specific manner.

    Goldgraben, Mae A / Russell, Roslin / Rueda, Oscar M / Caldas, Carlos / Git, Anna

    RNA (New York, N.Y.)

    2015  Band 22, Heft 2, Seite(n) 193–203

    Abstract: MicroRNAs are short (17-26) noncoding RNAs driving or modulating physiological and pathological cellular events. Overexpression of miR-155 is pathogenic in B-cell malignancy but was also reported in a number of solid tumors-in particular, in breast ... ...

    Abstract MicroRNAs are short (17-26) noncoding RNAs driving or modulating physiological and pathological cellular events. Overexpression of miR-155 is pathogenic in B-cell malignancy but was also reported in a number of solid tumors-in particular, in breast cancer, where its role remains unclear and often contradictory. Using representative cell line models, we sought to determine whether the discrepant miR-155 effects in breast cancer could be explained by the heterogeneity of the disease. The growth of six breast cancer cell lines transfected with several miRNA mimics was analyzed. We found MCF-7 cell growth to be inhibited by miR-155 and miR-145 mimics, both 23-nt long, but not by a number of shorter mimics, including a universal commercial negative control. Microarray and Western blot analyses revealed induction of apoptosis, associated with interferon-β after activation of the double-stranded RNA sensor pathway. 3' Trimming of the miRNA mimics to 21 nt substantially reduced their growth-inhibitory potency. Mutating the canonical seed of the miR-155 mimic had no effect on the induced inhibition, which was abolished by mutating the miRNA seed of the artificial passenger strand. A panel of breast cancer cell lines showed a wide range of sensitivities to 23-mer mimics, broadly consistent with the sensitivity of the cell lines to Poly (I:C). We demonstrate two sources for nonspecific in vitro effects by miRNA mimics: duplex length and the artificial passenger strand. We highlight the danger of a universal 21-mer negative control and the importance of using matched seed mutants for reliable interpretation of phenotypes.
    Mesh-Begriff(e) Apoptosis ; Cell Line, Tumor ; Cell Proliferation ; Epithelial Cells/metabolism ; Epithelial Cells/pathology ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Interferon-beta/biosynthesis ; Interferon-beta/genetics ; Mammary Glands, Human/metabolism ; Mammary Glands, Human/pathology ; MicroRNAs/genetics ; MicroRNAs/metabolism ; Microarray Analysis ; Molecular Mimicry ; Organ Specificity ; Poly I-C/genetics ; Poly I-C/metabolism ; RNA, Double-Stranded/genetics ; RNA, Double-Stranded/metabolism ; RNA, Small Interfering/genetics ; RNA, Small Interfering/metabolism ; Signal Transduction ; Structure-Activity Relationship
    Chemische Substanzen MicroRNAs ; RNA, Double-Stranded ; RNA, Small Interfering ; Interferon-beta (77238-31-4) ; Poly I-C (O84C90HH2L)
    Sprache Englisch
    Erscheinungsdatum 2015-12-15
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1241540-6
    ISSN 1469-9001 ; 1355-8382
    ISSN (online) 1469-9001
    ISSN 1355-8382
    DOI 10.1261/rna.054072.115
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  6. Artikel: There is no silver bullet--a guide to low-level data transforms and normalisation methods for microarray data.

    Kreil, David P / Russell, Roslin R

    Briefings in bioinformatics

    2005  Band 6, Heft 1, Seite(n) 86–97

    Abstract: To overcome random experimental variation, even for simple screens, data from multiple microarrays have to be combined. There are, however, systematic differences between arrays, and any bias remaining after experimental measures to ensure consistency ... ...

    Abstract To overcome random experimental variation, even for simple screens, data from multiple microarrays have to be combined. There are, however, systematic differences between arrays, and any bias remaining after experimental measures to ensure consistency needs to be controlled for. It is often difficult to make the right choice of data transformation and normalisation methods to achieve this end. In this tutorial paper we review the problem and a selection of solutions, explaining the basic principles behind normalisation procedures and providing guidance for their application.
    Mesh-Begriff(e) Algorithms ; Artifacts ; Calibration/standards ; Data Interpretation, Statistical ; Gene Expression Profiling/instrumentation ; Gene Expression Profiling/methods ; Gene Expression Profiling/standards ; Genetic Variation/genetics ; Models, Genetic ; Models, Statistical ; Numerical Analysis, Computer-Assisted ; Oligonucleotide Array Sequence Analysis/instrumentation ; Oligonucleotide Array Sequence Analysis/methods ; Oligonucleotide Array Sequence Analysis/standards ; Sequence Analysis, DNA/instrumentation ; Sequence Analysis, DNA/methods ; Sequence Analysis, DNA/standards
    Sprache Englisch
    Erscheinungsdatum 2005-01-12
    Erscheinungsland England
    Dokumenttyp Comparative Study ; Journal Article ; Review
    ZDB-ID 2068142-2
    ISSN 1467-5463
    ISSN 1467-5463
    DOI 10.1093/bib/6.1.86
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  7. Buch: Microarray technology in practice

    Russell, Steven / Meadows, Lisa Ann / Russell, Roslin R

    2009  

    Verfasserangabe Steven Russell, Lisa A. Meadows and Roslin R. Russell
    Schlagwörter DNA microarrays.
    Sprache Englisch
    Umfang x, 449 p., 4 p. of plates :, ill. (some col.) ;, 23 cm.
    Ausgabenhinweis 1st ed.
    Verlag Academic Press/Elsevier
    Erscheinungsort Amsterdam ; Boston
    Dokumenttyp Buch
    ISBN 9780123725165 ; 012372516X
    Datenquelle NAL Katalog (AGRICOLA)

    Zusatzmaterialien

    Kategorien

  8. Buch: Microarray technology in practice

    Russell, Steven / Meadows, Lisa Ann / Russell, Roslin R

    2009  

    Verfasserangabe Steven Russell, Lisa A. Meadows and Roslin R. Russell
    Mesh-Begriff(e) Oligonucleotide Array Sequence Analysis
    Sprache Englisch
    Umfang x, 449 p., [4] p. of plates :, ill. (some col.) ;, 23 cm.
    Ausgabenhinweis 1st ed.
    Verlag Elsevier/Academic Press
    Erscheinungsort Amsterdam ; Boston
    Dokumenttyp Buch
    ISBN 9780123725165 ; 012372516X
    Datenquelle Katalog der US National Library of Medicine (NLM)

    Zusatzmaterialien

    Kategorien

  9. Buch: Microarray technology in practice

    Meadows, Lisa Ann / Russell, Roslin R / Russell, Steven

    2009  

    Verfasserangabe [ed. by] Steven Russell; Lisa A. Meadows and Roslin R. Russell
    Sprache Englisch
    Umfang X, 449 S., Ill., graph. Darst., 23 cm
    Ausgabenhinweis 1. ed.
    Verlag Elsevier/Academic Press
    Erscheinungsort Amsterdam u.a.
    Dokumenttyp Buch
    Anmerkung Includes bibliographical references and index
    ISBN 012372516X ; 9780123725165
    Datenquelle Katalog der Technische Informationsbibliothek Hannover

    Zusatzmaterialien

    Kategorien

  10. Artikel ; Online: Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes.

    Joseph, Chitra / Macnamara, Olivia / Craze, Madeleine / Russell, Roslin / Provenzano, Elena / Nolan, Christopher C / Diez-Rodriguez, Maria / Sonbul, Sultan N / Aleskandarany, Mohammed A / Green, Andrew R / Rakha, Emad A / Ellis, Ian O / Mukherjee, Abhik

    British journal of cancer

    2018  Band 118, Heft 8, Seite(n) 1142–1151

    Abstract: Background: Mediator complex (MED) proteins have a key role in transcriptional regulation, some interacting with the oestrogen receptor (ER). Interrogation of the METABRIC cohort suggested that MED7 may regulate lymphovascular invasion (LVI). Thus MED7 ... ...

    Abstract Background: Mediator complex (MED) proteins have a key role in transcriptional regulation, some interacting with the oestrogen receptor (ER). Interrogation of the METABRIC cohort suggested that MED7 may regulate lymphovascular invasion (LVI). Thus MED7 expression was assessed in large breast cancer (BC) cohorts to determine clinicopathological significance.
    Methods: MED7 gene expression was investigated in the METABRIC cohort (n = 1980) and externally validated using bc-GenExMiner v4.0. Immunohistochemical expression was assessed in the Nottingham primary BC series (n = 1280). Associations with clinicopathological variables and patient outcome were evaluated.
    Results: High MED7 mRNA and protein expression was associated with good prognostic factors: low grade, smaller tumour size, good NPI, positive hormone receptor status (p < 0.001), and negative LVI (p = 0.04) status. Higher MED7 protein expression was associated with improved BC-specific survival within the whole cohort and ER+/luminal subgroup. Pooled MED7 gene expression data in the external validation cohort confirmed association with better survival, corroborating with the protein expression. On multivariate analysis, MED7 protein was independently predictive of longer BC-specific survival in the whole cohort and Luminal A subtype (p < 0.001).
    Conclusions: MED7 is an important prognostic marker in BC, particularly in ER+luminal subtypes, associated with improved survival and warrants future functional analysis.
    Mesh-Begriff(e) Adult ; Aged ; Biomarkers, Tumor/genetics ; Breast Neoplasms/classification ; Breast Neoplasms/diagnosis ; Breast Neoplasms/genetics ; Breast Neoplasms/mortality ; Cell Nucleus/genetics ; Cell Nucleus/metabolism ; Cohort Studies ; Female ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic ; Humans ; Mediator Complex/genetics ; Mediator Complex/physiology ; Middle Aged ; Neoplasm Invasiveness ; Prognosis ; Receptors, Estrogen/genetics ; Receptors, Estrogen/metabolism ; Survival Analysis
    Chemische Substanzen Biomarkers, Tumor ; MED7 protein, human ; Mediator Complex ; Receptors, Estrogen
    Sprache Englisch
    Erscheinungsdatum 2018-03-28
    Erscheinungsland England
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't ; Validation Studies
    ZDB-ID 80075-2
    ISSN 1532-1827 ; 0007-0920
    ISSN (online) 1532-1827
    ISSN 0007-0920
    DOI 10.1038/s41416-018-0041-x
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang